human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) Report issue

Vaccine Approved FDA
AACT PubChem

Active Ingredient History

NOW
  • Now
Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). It was developed by Merck & Co. High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. The HPV strains that Gardasil protects against are sexually transmitted, specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. HPV type 16 is responsible for almost 90% of HPV-positive oropharyngeal cancers, and the prevalence is higher in males than females. Though Gardasil does not treat existing infection, vaccination is still recommended for HPV-positive individuals, as it may protect against one or more different strains of the disease.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

4-valent hpv vaccine | both doses late | garaisil | gardasil | hpv vaccine | human papillomavirus 6,11,16,18 vaccine | human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant | human papillomavirus quadrivalent vaccine | human papillomavirus type 11 l1 protein /human papillomavirus type 16 l1 protein /human papillomavirus type 18 l1 protein/human papillomavirus type 6 l1 protein | human papillomavirus type 6 l1 protein / human papillomavirus type 11 l1 protein / human papillomavirus type 16 l1 protein / human papillomavirus type 18 l1 protein | human papillomavirus vaccine l1, type 6,11,16,18 | quadrivalen human papillomavirus vaccine | quadrivalent human papillomavirus vaccine | silgard | tetravalent vaccine | v501

Organizations (128)

Research & Development (128)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (60)

Approved Indications (1)


 

Papillomavirus Infections (approved 2006)

Experimental Indications - Clinical Trial Phases 1-4 (60)


 

Acne Vulgaris (Phase 2)

Adenocarcinoma in Situ (Phase 4)

Adolescent (Phase 1)

Alphapapillomavirus (Phase 4)

Androgens (Phase 3)

Anus Neoplasms (Phase 2)

Arthritis, Juvenile (Phase 3)

Autoimmune Diseases (Phase 3)

Bone Marrow Transplantation (Phase 3)

Cancer Survivors (Phase 2)

Carcinoma (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Verrucous (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 4)

Condylomata Acuminata (Phase 4)

Diphtheria (Phase 3)

Drugs, Investigational (Phase 2)

Genital Diseases, Female (Phase 2)

Genital Neoplasms, Female (Phase 3)

Healthy Volunteers (Phase 4)

Hematopoietic Stem Cell Transplantation (Phase 1)

HIV (Phase 4)

HIV Infections (Phase 3)

Human papillomavirus 16 (Phase 4)

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (Phase 4)

Humans (Phase 3)

Immune System Diseases (Phase 2)

Infections (Phase 4)

Inflammatory Bowel Diseases (Phase 3)

Kidney Transplantation (Phase 4)

Liver Transplantation (Phase 4)

Lung Diseases (Phase 3)

Lupus Erythematosus, Systemic (Phase 4)

Meningitis (Phase 3)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 2)

Meningococcal Vaccines (Phase 2)

Neoplasms (Phase 4)

Neoplasms, Glandular and Epithelial (Phase 3)

Oropharyngeal Neoplasms (Phase 2)

Papilloma (Phase 4)

Papillomaviridae (Phase 3)

Papillomavirus Infections (Phase 4)

Papillomavirus Vaccines (Phase 4)

Penile Neoplasms (Phase 2)

Pharmacological and Toxicological Phenomena (Phase 1)

Poliomyelitis (Phase 3)

Precancerous Conditions (Phase 4)

Sexually Transmitted Diseases (Phase 2)

Tetanus (Phase 3)

Transplantation (Phase 2)

Transplants (Phase 3)

Uterine Cervical Dysplasia (Phase 1)

Uterine Cervical Neoplasms (Phase 4)

Vaccine-Preventable Diseases (Phase 4)

Vaccines (Phase 2)

Vaginal Neoplasms (Phase 3)

Vulvar Neoplasms (Phase 3)

Warts (Phase 4)

Whooping Cough (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 122
  • # of Trial Organizations: 128

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue